Timing and impact of decisions to adjust disease-modifying antirheumatic drug therapy for rheumatoid arthritis patients with active disease

OBJECTIVE: Guidelines recommend that rheumatoid arthritis (RA) patients with moderate to high disease activity (MHDAS) adjust disease-modifying antirheumatic drug (DMARD) therapy at least every 3 months until reaching low disease activity or remission (LDAS). We examined how quickly RA patients with...

全面介紹

Na minha lista:
書目詳細資料
發表在:Arthritis Care Res (Hoboken)
Main Authors: Shaw, Yomei, Chang, Chung-Chou H., Levesque, Marc C., Donohue, Julie M., Michaud, Kaleb, Roberts, Mark S.
格式: Artigo
語言:Inglês
出版: 2018
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5862728/
https://ncbi.nlm.nih.gov/pubmed/28941147
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acr.23418
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍